Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Acceleron Pharma Inc.
Cambridge, Massachusetts, United Statesacceleronpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Acceleron has FDA-approved products including Reblozyl (luspatercept-aamt) for anemia in certain blood disorders and has advanced sotatercept to Phase 3 trials for pulmonary arterial hypertension.
- Therapeutic areas
- OncologyMetabolic DisordersHematologyOtherRheumatologyCardiovascularNeurology
- Modalities
- Protein therapeuticsFusion proteinsAntibody fusion proteins
- Industry
- Biotech
02
Partnerships
Bristol Myers Squibb (global collaboration for REBLOZYL)
Beyond the preview
Go deeper on Acceleron Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acceleron Pharma Inc..